Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q2 2018 Earnings Conference Call - Final Transcript
Aug 03, 2018 • 08:00 am ET
Good day, ladies and gentlemen and welcome to the Q2 2018 Aclaris Therapeutics, Inc. Earnings Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will follow at that time.
As a reminder, this conference call maybe recorded.
I would now like to introduce your host for today's conference, Kamil Ali-Jackson, Chief Legal Officer. You may begin.
Thank you, Krystal. I am Kamil Ali-Jackson, Chief Legal Officer for Aclaris.
Please note that earlier today, Aclaris issued its press release announcing second quarter 2018 financial results. For those of you who have not seen it yet, you will find the release posted in the Investors section of our website at www.aclaristx.com.
Joining me for the call today are Dr. Neal Walker, President and Chief Executive Officer, Chris Powala, our Chief Regulatory and Development Officer, Dr. Stuart Shanler, our Chief Scientific Officer, Frank Ruffo, our Chief Financial Officer, Brett Fair, our Chief Commercial Officer, and David Gordon, our Chief Medical Officer.
(Forward-Looking Cautionary Statements)
Please be advised that today's call is being recorded and webcast. A link to the webcast is posted in the Investors section of our website.
I'll now turn the call over to Dr. Neal Walker, President and CEO of Aclaris. Neal?
Thank you, Kamil. Good morning everyone.
I will start with a brief update of our clinical development programs and our other business highlights and then hand it off to Brett Fair, our Chief Commercial Officer who will address ESKATA launch. Next Stuart Shanler, our Chief Scientific Officer will review or clinical development plans and timelines after which Frank Ruffo, our CFO, will review our financial results. Following our prepared remarks we will open up the line to take your questions. Dr. David Gordon, our new Chief Medical Officer who recently joined us, will also be available during the Q&A portion of the call.
During the second quarter of 2018 after our national sales meeting at the beginning of May, we launched ESKATA 40% topical solution to both physicians and patients. During the first eight weeks of the launch which made up the bulk of the second quarter our field force made significant progress in accomplishing our primary goal of driving account option as we initiate our consumer campaigns in the back half of 2018. In addition to an exciting launch, we've also made good progress in advancing our pipeline during the second quarter.
In July we completed the end of Phase 2 meeting with the FDA regarding A-101 45% topical solution for the treatment of common warts otherwise known as verruca vulgaris and as expected we are on track to start the pivotal Phase 3 program in the second half of this year.
Regarding our JAK inhibitor program we dosed our first patient in a Phase 2 clinical trial of our oral JAK inhibitor ATI-501 in patients with Alopecia Areata which includes the more severe phenotypes of Alopecia Totalis and Universalis.
Turning to our early